Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Awareness

The legacy context of general health and science information has long provided foundational knowledge on a wide range of medical topics, including bone health and the safe use of pharmaceuticals. Within this broad framework, public awareness of medication side effects has been a consistent theme, emphasizing the importance of understanding risks associated with long-term therapies. Transitioning from this general health perspective, a specific area of concern emerges regarding the bisphosphonate drug Fosamax and its potential link to osteonecrosis of the jaw. This condition, involving bone death in the jaw, has been the subject of scientific inquiry to establish causation. The shift from a general health context to a focused occupational exposure concern is particularly relevant for professionals in dentistry, oral surgery, and related fields who may encounter patients with a history of Fosamax use. These practitioners must consider the implications of such exposure when planning invasive dental procedures. Thus, the bridge from broad health education to a targeted risk assessment for Fosamax and osteonecrosis of the jaw underscores the need for careful evaluation in clinical settings where occupational exposure to this medication history is a factor.

Fosamax: Mechanism and Recognized Adverse Effects

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling. A recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation and diagnosis of ONJ typically involve exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis relies on clinical examination and imaging, with exclusion of metastatic disease or other causes of jaw necrosis. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights that the jawbone's unique structure and remodeling dynamics may contribute to its vulnerability to bisphosphonate-induced damage.

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ involve its potent inhibition of osteoclast activity, which suppresses bone turnover. In the jaw, where remodeling is frequent due to dental function and infection, this suppression can impair healing after minor trauma or dental procedures. Bisphosphonates accumulate in bone matrix and are released over time, potentially leading to prolonged suppression of remodeling. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The combination of these factors with bisphosphonate therapy can precipitate ONJ.

Adequacy of Warnings and Causation Considerations

Regarding adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax. The label also notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping, though a subset had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event and may not be solely attributable to the drug. Causation-related considerations for affected patients require careful evaluation. While Fosamax is associated with ONJ, the condition can occur spontaneously in the absence of bisphosphonate use. The label emphasizes that ONJ is generally associated with tooth extraction and/or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Therefore, establishing causation in an individual patient involves assessing the temporal relationship, presence of other risk factors, and exclusion of alternative causes. The timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates attribution, as ONJ may develop after years of use or shortly after initiation. For patients who develop ONJ, management includes discontinuation of the bisphosphonate, conservative debridement, antibiotics, and oral hygiene measures. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, scientific evidence supports a connection between Fosamax and ONJ, with mechanistic plausibility through bisphosphonate-induced suppression of bone remodeling. The risk is increased with longer exposure and in the presence of dental procedures or other risk factors. Warnings in the prescribing information address this risk, but the rarity of ONJ and the presence of confounding factors require individualized assessment for causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

Scientific evidence shows that Fosamax (alendronate) inhibits bone resorption, which can suppress bone remodeling in the jaw, leading to impaired healing and potential bone death. Studies, including multiscale characterization of jawbone (https://pubmed.ncbi.nlm.nih.gov/40345077/), support the mechanistic plausibility. The prescribing information acknowledges ONJ as a reported adverse event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include longer duration of bisphosphonate use, invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is causation determined for an individual patient with Fosamax exposure and ONJ?

Causation assessment involves evaluating the temporal relationship between Fosamax use and ONJ onset (which can range from one day to several months), presence of other risk factors, and exclusion of alternative causes. The prescribing information notes that ONJ can occur spontaneously and is often associated with dental procedures or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.